Clinical Trial: First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06799065) titled 'First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer' on Jan. 18.

Brief Summary: The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.

Study Start Date: April 30, 2025

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors Breast Cancer Recurrent Ovarian Cancer High-grade Serous Ovarian Carcinoma...